Hospital
Aiken Regional Medical Centers LLC
Aiken Regional Medical Centers LLC was paid $31.51M by Medicaid between Jan 2018 and Dec 2024, across 275 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 29% of everything it billed.
33Billing provider infoAIKEN REGIONAL MEDICAL CENTERS LLC
AIKEN, SC 29801
AIKEN, SC 29801
33aNPI1467448498assigned 09/26/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$31.51M
24GClaims998,933
24DCodes billed275
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 149,880 | $4.90M | |
| 2019 | 165,560 | $4.57M | |
| 2020 | 121,443 | $3.47M | |
| 2021 | 130,134 | $4.63M | |
| 2022 | 142,143 | $4.85M | |
| 2023 | 153,516 | $5.32M | |
| 2024incomplete | 136,257 | $3.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 29% | 65,348 | 50,568 | $9.17M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10.0% | 38,637 | 32,228 | $3.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 40,403 | 36,729 | $1.79M |
| 59025 | Fetal non-stress test | 4.5% | 18,216 | 7,309 | $1.42M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.9% | 3,291 | 1,478 | $1.22M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 8,421 | 7,859 | $952K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.8% | 9,589 | 8,660 | $872K |
| 87070 | 2.6% | 6,429 | 5,937 | $811K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 11,425 | 3,818 | $670K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 6,247 | 5,551 | $629K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 12,364 | 10,028 | $484K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 6,479 | 6,243 | $449K |
263 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 3,594 | $433K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.3% | 2,764 | $420K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 3,654 | $402K |
| 80053 | Comprehensive metabolic panel | 1.0% | 42,245 | $319K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,068 | $304K |
| 81001 | <1% | 30,983 | $301K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,754 | $278K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,208 | $257K |
| 99284 | Emergency room visit (serious) | <1% | 29,319 | $250K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,313 | $232K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,824 | $215K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,639 | $212K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,580 | $207K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,753 | $206K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,162 | $198K |
| 81003 | <1% | 12,927 | $195K | |
| 81025 | <1% | 20,925 | $192K | |
| 82962 | <1% | 7,338 | $186K | |
| 73610 | <1% | 2,270 | $184K | |
| 73130 | <1% | 1,962 | $180K | |
| 73630 | <1% | 3,122 | $177K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,750 | $175K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,703 | $168K |
| 73564 | <1% | 2,867 | $155K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,696 | $145K |
| 82565 | <1% | 765 | $143K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,302 | $139K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,039 | $135K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,514 | $132K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 305 | $119K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 796 | $109K |
| 93971 | <1% | 1,300 | $104K | |
| 99285 | Emergency room visit (most serious) | <1% | 21,635 | $103K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,845 | $100K |
| 97597 | <1% | 1,734 | $100K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,013 | $97K |
| 80061 | Lipid panel | <1% | 2,799 | $95K |
| 87077 | <1% | 5,718 | $94K | |
| 84112 | <1% | 678 | $93K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,576 | $92K |
| 73110 | <1% | 1,250 | $90K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,076 | $90K |
| 73030 | <1% | 1,917 | $90K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,703 | $87K |
| 72100 | <1% | 2,479 | $86K | |
| 83655 | <1% | 1,822 | $82K | |
| 10060 | <1% | 248 | $75K | |
| 87420 | <1% | 737 | $70K | |
| 76775 | <1% | 1,160 | $61K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,898 | $51K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,804 | $47K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,991 | $47K |
| 93970 | <1% | 317 | $46K | |
| 74018 | <1% | 1,416 | $46K | |
| 80306 | <1% | 2,348 | $43K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,556 | $43K |
| 82948 | <1% | 3,652 | $42K | |
| 76642 | <1% | 983 | $41K | |
| 94010 | <1% | 131 | $41K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,093 | $41K |
| 87210 | <1% | 1,194 | $40K | |
| 72040 | <1% | 601 | $38K | |
| 76830 | Ultrasound, transvaginal | <1% | 455 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,499 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,406 | $35K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 860 | $34K |
| 73502 | <1% | 1,088 | $34K | |
| 0353U | <1% | 740 | $33K | |
| 12001 | <1% | 165 | $30K | |
| 87430 | <1% | 4,572 | $29K | |
| 73080 | <1% | 455 | $27K | |
| 82247 | <1% | 1,154 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 732 | $27K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,477 | $27K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,585 | $26K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,404 | $25K |
| 77066 | Tomosynthesis, mammo | <1% | 276 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,803 | $24K |
| 85027 | <1% | 9,364 | $24K | |
| 88312 | <1% | 1,152 | $22K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 86 | $21K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,072 | $18K |
| 76801 | <1% | 1,928 | $18K | |
| 93976 | <1% | 770 | $17K | |
| 73590 | <1% | 383 | $16K | |
| 99381 | <1% | 241 | $15K | |
| 76536 | <1% | 171 | $13K | |
| G0378 | Hospital observation service, per hour | <1% | 3,696 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 433 | $12K |
| 73090 | <1% | 218 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,062 | $12K |
| 82731 | <1% | 154 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $12K |
| 84439 | <1% | 1,702 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $9K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 701 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 403 | $8K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,474 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 990 | $8K |
| 81002 | <1% | 177 | $8K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 51 | $7K |
| 71250 | <1% | 72 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,183 | $7K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 908 | $7K |
| 96376 | <1% | 1,743 | $7K | |
| 97162 | <1% | 154 | $7K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 63 | $6K |
| 97161 | <1% | 102 | $6K | |
| 88304 | <1% | 631 | $5K | |
| 86850 | <1% | 4,288 | $5K | |
| 95816 | <1% | 26 | $4K | |
| 82810 | <1% | 174 | $4K | |
| 97116 | <1% | 1,588 | $4K | |
| 86140 | <1% | 347 | $4K | |
| 93975 | <1% | 111 | $3K | |
| 74178 | <1% | 13 | $3K | |
| 87040 | <1% | 4,555 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,043 | $3K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 104 | $3K |
| 12011 | <1% | 12 | $3K | |
| 72072 | <1% | 85 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 411 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 726 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 227 | $3K |
| 70486 | <1% | 98 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 394 | $3K |
| 84484 | <1% | 18,444 | $3K | |
| 83880 | <1% | 7,108 | $2K | |
| A9270 | Non-covered item or service | <1% | 28,828 | $2K |
| 85018 | <1% | 275 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,167 | $2K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,156 | $2K |
| 82803 | <1% | 1,698 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,785 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,285 | $2K |
| 74240 | <1% | 13 | $2K | |
| 84702 | <1% | 4,974 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,122 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,805 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,232 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,319 | $1K |
| 82375 | <1% | 133 | $1K | |
| 83690 | <1% | 19,781 | $1K | |
| 93017 | <1% | 29 | $1K | |
| 73140 | <1% | 16 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 959 | $1K |
| 83735 | <1% | 9,680 | $1K | |
| 83540 | <1% | 38 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,486 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,352 | $1K |
| 86592 | <1% | 410 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,825 | $1K |
| 82570 | <1% | 452 | $975.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,498 | $924.97 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,994 | $909.41 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 232 | $907.64 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,616 | $901.97 |
| 80076 | <1% | 2,603 | $893.59 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 855 | $836.54 |
| 74022 | <1% | 45 | $791.76 | |
| 85379 | <1% | 3,011 | $709.99 | |
| 72170 | <1% | 51 | $689.05 | |
| 97165 | <1% | 24 | $686.81 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 108 | $650.91 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 308 | $629.39 |
| 87186 | <1% | 5,734 | $599.65 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,847 | $599.61 |
| 86900 | <1% | 6,255 | $582.38 | |
| 81005 | <1% | 480 | $579.61 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 25 | $547.76 |
| 83615 | <1% | 450 | $523.94 | |
| 70491 | <1% | 13 | $502.74 | |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $473.16 |
| 82272 | <1% | 57 | $467.55 | |
| 82330 | <1% | 37 | $434.63 | |
| 73060 | <1% | 14 | $414.07 | |
| 85610 | <1% | 6,611 | $402.56 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,154 | $401.96 |
| C1769 | Guide wire | <1% | 334 | $389.99 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,684 | $376.61 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 320 | $372.49 |
| 85730 | <1% | 5,994 | $371.34 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 373 | $350.62 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 28 | $332.22 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 33 | $329.11 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 200 | $279.17 |
| 90670 | <1% | 15 | $266.55 | |
| 87806 | <1% | 1,084 | $264.26 | |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $258.88 |
| 83986 | <1% | 13 | $224.69 | |
| 83605 | <1% | 4,087 | $204.60 | |
| 84100 | <1% | 508 | $202.43 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,913 | $190.24 |
| 84156 | <1% | 633 | $183.76 | |
| 86901 | <1% | 6,256 | $149.08 | |
| 90686 | <1% | 30 | $131.39 | |
| 87899 | <1% | 1,790 | $117.58 | |
| 82550 | <1% | 1,456 | $117.39 | |
| 90461 | <1% | 1,228 | $106.99 | |
| 90715 | <1% | 1,199 | $101.60 | |
| 82010 | <1% | 442 | $71.40 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 1,584 | $69.36 |
| 88342 | <1% | 14 | $49.30 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,038 | $33.24 |
| G0009 | Administration of pneumococcal vaccine | <1% | 317 | $31.02 |
| 90633 | <1% | 62 | $29.55 | |
| 88302 | <1% | 12 | $14.17 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,213 | $10.68 |
| 83050 | <1% | 130 | $6.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,477 | $4.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,163 | $3.09 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 112 | $1.09 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 181 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 164 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 90 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 630 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 77 | $0.00 |
| 36430 | 0% | 31 | $0.00 | |
| 70498 | 0% | 12 | $0.00 | |
| 86920 | 0% | 19 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 86 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 27 | $0.00 |
| 85651 | 0% | 140 | $0.00 | |
| 87205 | 0% | 152 | $0.00 | |
| 90651 | 0% | 20 | $0.00 | |
| 87640 | 0% | 67 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 147 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| 80069 | 0% | 13 | $0.00 | |
| 87340 | 0% | 24 | $0.00 | |
| 88307 | 0% | 12 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 24 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 28 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 17 | $0.00 |
| 84132 | 0% | 34 | $0.00 | |
| 85652 | 0% | 17 | $0.00 | |
| 82248 | 0% | 1,038 | $0.00 | |
| 80164 | 0% | 13 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 424 | $0.00 |
| 87075 | 0% | 53 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 1,061 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 241 | $0.00 |
| 84550 | 0% | 640 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 29 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 600 | $0.00 |
| 85384 | 0% | 100 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 145 | $0.00 |
| 85014 | 0% | 58 | $0.00 | |
| 87641 | 0% | 166 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 173 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 56 | $0.00 |
| 84295 | 0% | 19 | $0.00 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 15 | $0.00 |
| 96367 | 0% | 16 | $0.00 | |
| 94727 | 0% | 28 | $0.00 | |
| 93925 | 0% | 14 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 30 | $0.00 |
| 82947 | 0% | 23 | $0.00 | |
| 84520 | 0% | 19 | $0.00 | |
| 99152 | 0% | 27 | $0.00 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.